Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eight newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, effective August 3, 2026, in line with Nasdaq Listing Rule 5635(c)(4).
The grants cover non-statutory stock options for up to 53,975 shares at an exercise price of $8.40 per share with a ten-year term, plus restricted stock units for 17,450 shares. Options vest over four years (25% after one year, then monthly for three years) and RSUs vest in three equal annual installments, all subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Earlier inducement-grant announcements showed both a -3.23% and 1.45% 24-hour reaction, adding a mix...
Analysis
Earlier inducement-grant announcements showed both a -3.23% and 1.45% 24-hour reaction, adding a mixed historical frame to this award notice. The active S-3ASR shelf and Net Selling insider sentiment were relevant background.
Key Figures
Newly hired employees:8 employeesStock options:53,975 sharesRestricted stock units:17,450 shares+5 more
"today announced that it has granted inducement equity awards to eight newly hired"
Inducement equity awards are stock-based grants—such as shares or options—given to newly hired employees or executives as a hiring incentive, often issued outside a company’s standard long-term compensation plan. They matter to investors because they dilute existing ownership, create a charge against earnings, and align new hires’ pay with company performance; think of it as giving a slice of the pie upfront to convince someone to join, which changes each owner’s share and incentives.
non-statutory stock option awardsfinancial
"consist of non-statutory stock option awards to purchase up to an aggregate"
A non-statutory stock option award is a company grant that gives an employee or contractor the right to buy company shares at a set price, but that is not part of tax-qualified plans under specific laws. Like a coupon to buy stock later, these options can create share dilution, require the company to report compensation expense, and trigger ordinary income tax for the holder at exercise, matters investors watch when assessing shareholder value and earnings.
restricted stock unit awardsfinancial
"and restricted stock unit awards representing the right to receive an aggregate"
Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of August 3, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 53,975 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 17,450 shares of Ocular’s common stock.The stock option awards have an exercise price of $8.40 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant.Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com
FAQ
What inducement equity grants did Ocular Therapeutix (NASDAQ: OCUL) announce on August 7, 2026?
Ocular Therapeutix announced inducement equity awards to eight new non-executive employees, including stock options and restricted stock units. According to Ocular Therapeutix, these grants were made under its 2019 Inducement Stock Incentive Plan and structured to comply with Nasdaq Listing Rule 5635(c)(4).
How many Ocular Therapeutix (OCUL) shares are covered by the new inducement stock options and RSUs?
The inducement awards cover options to purchase up to 53,975 shares and RSUs for 17,450 shares of common stock. According to Ocular Therapeutix, these figures represent the aggregate amounts granted across the eight newly hired non-executive employees on August 3, 2026.
What is the exercise price and term of the new Ocular Therapeutix (OCUL) inducement stock options?
The new stock options have an exercise price of $8.40 per share and a ten-year term. According to Ocular Therapeutix, the exercise price equals the August 3, 2026 closing price of its common stock on The Nasdaq Global Market, the effective grant date.
How do the Ocular Therapeutix (OCUL) inducement stock options vest for new employees?
The stock options vest over four years, with 25% vesting on the first anniversary and the rest monthly over three years. According to Ocular Therapeutix, vesting is contingent on each recipient’s continued service through the applicable vesting dates.
What is the vesting schedule for the Ocular Therapeutix (OCUL) inducement restricted stock units?
The inducement restricted stock units vest in three equal annual installments over three years. According to Ocular Therapeutix, vesting occurs on the first, second, and third anniversaries of the grant date, subject to continued service by each recipient.
Under which plan were the August 2026 Ocular Therapeutix (OCUL) inducement awards granted?
The inducement awards were granted under Ocular Therapeutix’s 2019 Inducement Stock Incentive Plan. According to Ocular Therapeutix, the grants are also governed by specific award agreements that set detailed terms and conditions for the stock options and restricted stock units.
